PATENT CLAIM ANALYSIS

Application Number: 15884915
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "676000"]

Abstract:
The present invention relates to a method of treating or preventing cellular dysfunction and death caused by genetic, degenerative, toxic, traumatic, ischemic, infectious, neoplastic and inflammatory diseases and aging—and their neurological symptoms and manifestations, which includes administering d-methadone, beta-d-methadol, alpha-l-methadol, beta-l-methadol, alpha-d-methadol, acetylmethadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, beta-d-acetylmethadol, beta-l-acetylmethadol, d-alpha-normethadol, l-alpha normethadol, noracetylmethadol, dinoracetylmethadol, methadol, normethadol, dinormethadol, EDDP, EMDP, d-isomethadone, normethadone, N-methyl-methadone, N-methyl-d-methadone, N-methyl-l-methadone, l-moramide, levopropoxyphene, pharmaceutically acceptable salts, or mixtures thereof, including deuterated and tritium analogues, whether isolated from its enantiomer or synthesized de novo.

Claim (Index 13):
The method of  claim 1 , wherein the nervous system disorder is chosen from Alzheimer's disease; presenile dementia; senile dementia; vascular dementia; Lewy body dementia; cognitive impairment; Parkinson's disease; Parkinsonian related disorders; disorders associated with accumulation of beta amyloid protein; disorders associated with accumulation or disruption of tau protein and its metabolites, frontal variant, primary progressive aphasias, semantic dementia, progressive non fluent aphasia, corticobasal degeneration, supranuclear palsy; epilepsy; NS trauma; NS infections; NS inflammation, cytopathology from toxins; stroke; multiple sclerosis; Huntington's disease; mitochondrial disorders; Leigh syndrome; LHON; Fragile X syndrome; Angelman syndrome; hereditary ataxias; neuro-otological and eye movement disorders; neurodegenerative diseases of the retina; amyotrophic lateral sclerosis; tardive dyskinesias; hyperkinetic disorders; attention deficit hyperactivity disorder; attention deficit disorders; restless leg syndrome; Tourette's syndrome; schizophrenia; autism spectrum disorders; tuberous sclerosis; Rett syndrome; cerebral palsy; disorders of the reward system; binge eating disorder; trichotillomania; dermotillomania; nail biting; migraine; fibromyalgia; and peripheral neuropathy of any etiology.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 86.0
- Lexical Diversity: 1.53165
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13803375', '15204052', '11527757', '13344393', '15579461']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7885850366519036
- 35 USC 102 Novelty (BERT): 0.5443534914790301
- Combined Prediction Score: 0.7641618821346163
- Mean Citation Score: 297.347038
- Max Citation Score: 403.17282
- Similarity Product: 269.56460082276107

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test